Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

July 2021

Axxam announces the launch of Muna Therapeutics ApS with EUR 60 Million to advance novel small molecule therapeutics for neurodegenerative diseases


Axxam has announced that Muna Therapeutics, a biotech company founded in 2020 by Aarhus University, financed by Novo Seeds and receiving assets in exchange of equity from Axxam, was successful closing a EUR 60 million (US$ 73 million) Series A financing round.
 
The investor syndicate was co-led by Novo Holdings, Sofinnova Partners, LSP Dementia Fund, and Droia Ventures, with Polaris Partners, Polaris Innovation Fund, Sanofi Ventures and V-Bio Ventures joining the round.
Axxam has the strategy of taking equity in promising drug discovery companies, by assigning valuable research assets either to already formed companies, such as Acousia Therapeutics GmbH or Muna Therapeutics ApS, as well as to start-ups, such as Rewind Therapeutics NV or Libra Therapeutics, Inc. Since 2016, these four drug discovery companies have collected more than EUR 110 million to advance the drug discovery programs transferred from Axxam into later stage development products.
read the press release
Zoner

AXXAM

Axxam SpA is a privately owned iPRO (innovative Partner Research Organization) and discovery company located at the Science Park OpenZone in Bresso (Milan, Italy). The Company is a leading provider of discovery services for the entire life sciences industry including pharmaceutical, crop protection, animal health, cosmetics and nutrition.
Axxam